GMAB – Genmab A/S
Genmab A/SGMAB
$21.78Name : Genmab A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,395,245,056.00
EPSttm : 1.7
Genmab A/S
$21.78
0.51%$0.11Float Short %
0.6
Margin Of Safety %
40
Put/Call OI Ratio
0.48
EPS Next Q Diff
0.12
EPS Last/This Y
-0.36
EPS This/Next Y
0.12
Price
21.78
Target Price
31.46
Analyst Recom
1.71
Performance Q
4.06
Relative Volume
0.88
Beta
0.95
Ticker: GMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | GMAB | 20.3 | 0.54 | 0.17 | 3212 |
| 2025-07-07 | GMAB | 20.52 | 0.54 | 0.18 | 3245 |
| 2025-07-08 | GMAB | 21.25 | 0.54 | 0.10 | 3251 |
| 2025-07-09 | GMAB | 21.58 | 0.53 | 0.00 | 3265 |
| 2025-07-10 | GMAB | 21.85 | 0.53 | 0.00 | 3273 |
| 2025-07-11 | GMAB | 21.4 | 0.53 | 1.77 | 3278 |
| 2025-07-14 | GMAB | 21.47 | 0.54 | 0.11 | 3307 |
| 2025-07-15 | GMAB | 21.16 | 0.54 | 0.17 | 3306 |
| 2025-07-16 | GMAB | 21.86 | 0.54 | 0.04 | 3330 |
| 2025-07-17 | GMAB | 22.01 | 0.53 | 0.18 | 3341 |
| 2025-07-18 | GMAB | 21.88 | 0.53 | 0.13 | 3343 |
| 2025-07-21 | GMAB | 21.7 | 0.47 | 0.73 | 3364 |
| 2025-07-22 | GMAB | 21.81 | 0.48 | 1.50 | 3394 |
| 2025-07-23 | GMAB | 22.86 | 0.48 | 0.23 | 3396 |
| 2025-07-24 | GMAB | 23.62 | 0.48 | 0.20 | 3449 |
| 2025-07-25 | GMAB | 23.42 | 0.48 | 0.29 | 3447 |
| 2025-07-28 | GMAB | 23.09 | 0.48 | 0.00 | 3450 |
| 2025-07-29 | GMAB | 22.6 | 0.48 | 0.17 | 3453 |
| 2025-07-30 | GMAB | 22.27 | 0.48 | 0.00 | 3454 |
| 2025-07-31 | GMAB | 21.66 | 0.48 | 0.42 | 3460 |
| 2025-08-01 | GMAB | 21.77 | 0.48 | 0.07 | 3457 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | GMAB | 20.30 | 23.9 | 42.5 | 1.41 |
| 2025-07-07 | GMAB | 20.52 | 23.9 | 74.1 | 1.41 |
| 2025-07-08 | GMAB | 21.25 | 23.9 | 116.0 | 1.41 |
| 2025-07-09 | GMAB | 21.58 | 23.9 | 69.9 | 1.41 |
| 2025-07-10 | GMAB | 21.86 | 23.9 | 82.7 | 1.41 |
| 2025-07-11 | GMAB | 21.40 | 23.9 | 45.3 | 1.41 |
| 2025-07-14 | GMAB | 21.46 | 23.9 | 42.7 | 1.41 |
| 2025-07-15 | GMAB | 21.15 | 23.9 | 25.7 | 1.41 |
| 2025-07-16 | GMAB | 21.87 | 23.9 | 99.7 | 1.41 |
| 2025-07-17 | GMAB | 22.01 | 23.9 | 54.4 | 1.41 |
| 2025-07-18 | GMAB | 21.88 | 23.9 | 26.3 | 1.41 |
| 2025-07-21 | GMAB | 21.70 | 23.9 | 14.1 | 1.41 |
| 2025-07-22 | GMAB | 21.81 | 23.9 | 56.5 | 1.41 |
| 2025-07-23 | GMAB | 22.87 | 23.9 | 147.9 | 1.41 |
| 2025-07-24 | GMAB | 23.63 | 5.9 | 121.9 | 1.34 |
| 2025-07-25 | GMAB | 23.40 | 5.9 | 104.5 | 1.34 |
| 2025-07-28 | GMAB | 23.12 | 5.9 | 34.6 | 1.34 |
| 2025-07-29 | GMAB | 22.60 | 5.9 | -11.1 | 1.34 |
| 2025-07-30 | GMAB | 22.27 | 5.9 | 3.2 | 1.34 |
| 2025-07-31 | GMAB | 21.67 | 5.9 | -36.6 | 1.34 |
| 2025-08-01 | GMAB | 21.78 | 5.9 | -28.3 | 1.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | GMAB | 0 | -0.09 | 0.36 |
| 2025-07-07 | GMAB | 0 | -0.25 | 0.36 |
| 2025-07-08 | GMAB | 0 | -0.25 | 0.36 |
| 2025-07-09 | GMAB | 0 | -0.25 | 0.36 |
| 2025-07-10 | GMAB | 0 | -0.25 | 0.36 |
| 2025-07-11 | GMAB | 0 | -0.25 | 0.28 |
| 2025-07-14 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-15 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-16 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-17 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-18 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-21 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-22 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-23 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-24 | GMAB | 0 | -0.29 | 0.28 |
| 2025-07-25 | GMAB | 0 | -0.29 | 0.60 |
| 2025-07-28 | GMAB | 0 | -0.37 | 0.60 |
| 2025-07-29 | GMAB | 0 | -0.37 | 0.60 |
| 2025-07-30 | GMAB | 0 | -0.37 | 0.60 |
| 2025-07-31 | GMAB | 0 | -0.37 | 0.60 |
| 2025-08-01 | GMAB | 0 | -0.37 | 0.60 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.31
Avg. EPS Est. Current Quarter
0.34
Avg. EPS Est. Next Quarter
0.43
Insider Transactions
Institutional Transactions
-0.37
Beta
0.95
Average Sales Estimate Current Quarter
5927
Average Sales Estimate Next Quarter
6152
Fair Value
30.58
Quality Score
100
Growth Score
97
Sentiment Score
12
Actual DrawDown %
55.6
Max Drawdown 5-Year %
-63.1
Target Price
31.46
P/E
12.35
Forward P/E
11.85
PEG
1.17
P/S
4.14
P/B
2.61
P/Free Cash Flow
11.5
EPS
1.76
Average EPS Est. Cur. Y
1.34
EPS Next Y. (Est.)
1.46
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
35.11
Relative Volume
0.88
Return on Equity vs Sector %
-3
Return on Equity vs Industry %
15.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.07
EBIT Estimation
-28.3
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 2638
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading